Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 4/2021

01-08-2021 | Schizophrenia | Research Article

Prescribing patterns of psychotropic medications in psychiatric disorders: a descriptive study from Palestine

Authors: Suhaib Hattab, Layth Qasarweh, Malek Ahmaro, Yazid Atatre, Yasin Tayem, Mazen Ali, Haitham Jahrami

Published in: International Journal of Clinical Pharmacy | Issue 4/2021

Login to get access

Abstract

Background The practice patterns of psychiatrists have changed over the last two decades. Objectives This study describes the pattern of prescribing psychotropic drugs in treating common psychiatric disorders, and investigates the rate of polypharmacy and potential drug-drug interactions. Setting Psychiatry governmental outpatient clinic in the north of West Bank, Palestine. Methods Cross-sectional study that included all prescriptions which were issued over the period October 2018 to January 2019, for patients diagnosed with schizophrenia, depression, anxiety, bipolar disorder and schizoaffective disorders, and checked for the presence and the grade of potential drug-drug interactions using “Medscape drug interactions checker". Main outcome measure Prescribing patterns of psychotropic drugs. Results A total of 1045 prescriptions were examined. The mean age of the patients was 47.3 years (SD = 13.6), two-thirds of the patients (64.5%) were males. Fifty-two percent of the patients were diagnosed with schizophrenia while 15.2% were diagnosed with depression. The later third was diagnosed with bipolar disorder, schizoaffective and anxiety disorders (15.8%, 11.1% and 5.1% respectively). The most commonly prescribed drugs were typical antipsychotics for schizophrenia, bipolar and schizoaffective disorders, selective serotonin reuptake inhibitors for depression and tricyclic anti-depressants for anxiety. Polypharmacy was found in 877 prescriptions (84%), and drug-drug interactions (DDIs) were identified in 823 (94%) prescriptions. The DDIs were classified as minor (4, 0.5%), significant (418, 50.8%) and serious (401, 48.7%). Conclusions Our results suggest that the pharmacotherapy of psychiatric disorders in Palestine may not be in accordance to international guidelines and the incidence of polypharmacy and DDIs is high.
Literature
2.
go back to reference MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ. 2003;326(7397):1014.CrossRef MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ. 2003;326(7397):1014.CrossRef
4.
go back to reference De Cuevas Las C, Sanz EJ. Polypharmacy in psychiatric practice in the Canary Islands. BMC Psychiatry. 2004;4:18.CrossRef De Cuevas Las C, Sanz EJ. Polypharmacy in psychiatric practice in the Canary Islands. BMC Psychiatry. 2004;4:18.CrossRef
5.
go back to reference Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatry Serv Wash DC. 2006;57(8):1094–101.CrossRef Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatry Serv Wash DC. 2006;57(8):1094–101.CrossRef
6.
go back to reference Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67(1):26–36.CrossRef Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67(1):26–36.CrossRef
7.
go back to reference Kukreja S, Kalra G, Shah N, Shrivastava A. Polypharmacy in psychiatry: a review. Mens Sana Monogr. 2013;11(1):82–99.CrossRef Kukreja S, Kalra G, Shah N, Shrivastava A. Polypharmacy in psychiatry: a review. Mens Sana Monogr. 2013;11(1):82–99.CrossRef
8.
go back to reference Freudenreich O, Kontos N, Querques J. Psychiatric polypharmacy: a clinical approach based on etiology and differential diagnosis. Harv Rev Psychiatry. 2012;20(2):79–85.CrossRef Freudenreich O, Kontos N, Querques J. Psychiatric polypharmacy: a clinical approach based on etiology and differential diagnosis. Harv Rev Psychiatry. 2012;20(2):79–85.CrossRef
9.
go back to reference Chong S-A, Ravichandran N, Poon L-Y, Soo K-L, Verma S. Reducing polypharmacy through the introduction of a treatment algorithm: use of a treatment algorithm on the impact on polypharmacy. Ann Acad Med Singapore. 2006;35(7):457–60.PubMed Chong S-A, Ravichandran N, Poon L-Y, Soo K-L, Verma S. Reducing polypharmacy through the introduction of a treatment algorithm: use of a treatment algorithm on the impact on polypharmacy. Ann Acad Med Singapore. 2006;35(7):457–60.PubMed
10.
go back to reference Procyshyn RM, Kennedy NB, Tse G, Thompson B. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry Rev Can Psychiatry. 2001;46(4):334–9.CrossRef Procyshyn RM, Kennedy NB, Tse G, Thompson B. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry Rev Can Psychiatry. 2001;46(4):334–9.CrossRef
11.
go back to reference Grüber L, Falkai P, Hasan A. Depressive symptoms in schizophrenia. Fortschr Neurol Psychiatry. 2015;83(4):238–46 (quiz 247–8).CrossRef Grüber L, Falkai P, Hasan A. Depressive symptoms in schizophrenia. Fortschr Neurol Psychiatry. 2015;83(4):238–46 (quiz 247–8).CrossRef
12.
go back to reference Sernyak MJ, Rosenheck R. Clinicians’ reasons for antipsychotic coprescribing. J Clin Psychiatry. 2004;65(12):1597–600.CrossRef Sernyak MJ, Rosenheck R. Clinicians’ reasons for antipsychotic coprescribing. J Clin Psychiatry. 2004;65(12):1597–600.CrossRef
13.
go back to reference Tanaka E, Hisawa S. Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. J Clin Pharm Ther. 1999;24(1):7–16.CrossRef Tanaka E, Hisawa S. Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. J Clin Pharm Ther. 1999;24(1):7–16.CrossRef
14.
go back to reference Preskorn SH. Drug-drug interactions in psychiatric practice, part 1: reasons, importance, and strategies to avoid and recognize them. J Psychiatry Pract. 2018;24(4):261–8.CrossRef Preskorn SH. Drug-drug interactions in psychiatric practice, part 1: reasons, importance, and strategies to avoid and recognize them. J Psychiatry Pract. 2018;24(4):261–8.CrossRef
15.
go back to reference Marie M, Hannigan B, Jones A. Mental health needs and services in the West Bank. Palestine Int J Ment Health Syst. 2016;10:23.CrossRef Marie M, Hannigan B, Jones A. Mental health needs and services in the West Bank. Palestine Int J Ment Health Syst. 2016;10:23.CrossRef
16.
go back to reference Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V, et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. Int J Epidemiol. 2014;43(2):476–93.CrossRef Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V, et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. Int J Epidemiol. 2014;43(2):476–93.CrossRef
17.
go back to reference Baxter AJ, Charlson FJ, Cheng HG, Shidhaye R, Ferrari AJ, Whiteford HA. Prevalence of mental, neurological, and substance use disorders in China and India: a systematic analysis. Lancet Psychiatry. 2016;3(9):832–41.CrossRef Baxter AJ, Charlson FJ, Cheng HG, Shidhaye R, Ferrari AJ, Whiteford HA. Prevalence of mental, neurological, and substance use disorders in China and India: a systematic analysis. Lancet Psychiatry. 2016;3(9):832–41.CrossRef
18.
go back to reference Tayem Y, Jahrami H, Ali M, Hattab S. Ambulatory pharmacotherapy of five psychiatric disorders in Bahrain: a descriptive study. Psychiatr Q. 2020;91(2):289–98.CrossRef Tayem Y, Jahrami H, Ali M, Hattab S. Ambulatory pharmacotherapy of five psychiatric disorders in Bahrain: a descriptive study. Psychiatr Q. 2020;91(2):289–98.CrossRef
19.
go back to reference Ren XS, Huang Y-H, Lee AF, Miller DR, Qian S, Kazis L. Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia. J Clin Pharm Ther. 2005;30(1):65–71.CrossRef Ren XS, Huang Y-H, Lee AF, Miller DR, Qian S, Kazis L. Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia. J Clin Pharm Ther. 2005;30(1):65–71.CrossRef
20.
go back to reference Azorin J-M, Kaladjian A, Fakra E. Current issues on schizoaffective disorder. L’Encephale. 2005;31(3):359–65.CrossRef Azorin J-M, Kaladjian A, Fakra E. Current issues on schizoaffective disorder. L’Encephale. 2005;31(3):359–65.CrossRef
21.
go back to reference Wang S-M, Han C, Bahk W-M, Lee S-J, Patkar AA, Masand PS, et al. Addressing the side effects of contemporary antidepressant drugs: a comprehensive review. Chonnam Med J. 2018;54(2):101–12.CrossRef Wang S-M, Han C, Bahk W-M, Lee S-J, Patkar AA, Masand PS, et al. Addressing the side effects of contemporary antidepressant drugs: a comprehensive review. Chonnam Med J. 2018;54(2):101–12.CrossRef
22.
go back to reference DeFilippis M, Wagner KD. Management of treatment-resistant depression in children and adolescents. Pediatr Drugs. 2014;16(5):353–61.CrossRef DeFilippis M, Wagner KD. Management of treatment-resistant depression in children and adolescents. Pediatr Drugs. 2014;16(5):353–61.CrossRef
23.
go back to reference Müller-Oerlinghausen B, Berghöfer A, Bauer M. Bipolar disorder. The Lancet. 2002;359(9302):241–7.CrossRef Müller-Oerlinghausen B, Berghöfer A, Bauer M. Bipolar disorder. The Lancet. 2002;359(9302):241–7.CrossRef
24.
go back to reference Baird-Gunning J, Lea-Henry T, Hoegberg LCG, Gosselin S, Roberts DM. Lithium poisoning. J Intensive Care Med. 2017;32(4):249–63.CrossRef Baird-Gunning J, Lea-Henry T, Hoegberg LCG, Gosselin S, Roberts DM. Lithium poisoning. J Intensive Care Med. 2017;32(4):249–63.CrossRef
25.
go back to reference Bespalov AY, van Gaalen MM, Gross G. Antidepressant treatment in anxiety disorders. Curr Top Behav Neurosci. 2010;2:361–90.CrossRef Bespalov AY, van Gaalen MM, Gross G. Antidepressant treatment in anxiety disorders. Curr Top Behav Neurosci. 2010;2:361–90.CrossRef
26.
go back to reference Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93–107.CrossRef Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93–107.CrossRef
Metadata
Title
Prescribing patterns of psychotropic medications in psychiatric disorders: a descriptive study from Palestine
Authors
Suhaib Hattab
Layth Qasarweh
Malek Ahmaro
Yazid Atatre
Yasin Tayem
Mazen Ali
Haitham Jahrami
Publication date
01-08-2021
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 4/2021
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01223-w

Other articles of this Issue 4/2021

International Journal of Clinical Pharmacy 4/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.